17-43047694-G-C
Variant summary
Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM1BP4_ModerateBP6
The NM_007294.4(BRCA1):āc.5416C>Gā(p.Pro1806Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000929 in 1,613,996 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P1806L) has been classified as Likely benign.
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Fanconi anemia, complementation group SInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 4Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -1 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| BRCA1 | NM_007294.4 | c.5416C>G | p.Pro1806Ala | missense_variant | Exon 22 of 23 | ENST00000357654.9 | NP_009225.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | ENST00000357654.9 | c.5416C>G | p.Pro1806Ala | missense_variant | Exon 22 of 23 | 1 | NM_007294.4 | ENSP00000350283.3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152118Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000119 AC: 3AN: 251484 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461878Hom.: 0 Cov.: 31 AF XY: 0.00000963 AC XY: 7AN XY: 727240 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152118Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74312 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:3
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
BS3, BP4 c.5416C>G, located in exon 22 (23 according to BIC nomenclature) of the BRCA1 gene, is predicted to result in the substitution of proline by alanine at codon 1806, p.(Pro1806Ala). This position affects a (potentially) clinically important functional domain and, moreover, the SpliceAI algorithm predicts no significant impact on splicing (BP4). This variant is found in 3/236948 alleles at a frequency of 0.001% in the gnomAD v2.1.1 database, non-cancer dataset. Reported by two calibrated studies to affect protein function similar to benign control variants (PMIDs:30209399, 30765603) (BS3). In a case-control study, this variant was present in 1 out of 53461 healthy controls and none of 60466 breast cancer patients (PMID: 33471991). This variant has been reported in the ClinVar database (4x likely benign, 2x uncertain significance), in the LOVD (6x unclassified) and in BRCA Exchange database (not yet classified by the expert panel). Based on currently available information, the variant c.5416C>G should be considered a likely benign variant, according to ClinGen ENIGMA BRCA1 and BRCA2 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for BRCA1 Version 1.0.0.
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:2
This missense variant replaces proline with alanine at codon 1806 of the BRCA1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Functional studies have reported that this variant does not impact BRCA1 activity in a haploid cell proliferation assay, transcription activation assays, and in protease sensitivity and phospho-peptide binding assays (PMID: 10811118, 15172985, 17308087, 20516115, 30209399). This variant has been detected in a breast cancer case-control meta-analysis in 0/60466 cases and 1/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_000472). This variant has been identified in 3/251484 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Although there is a suspicion that this variant may not be associated with disease, additional clinical studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
not specified Benign:1
Variant summary: BRCA1 c.5416C>G (p.Pro1806Ala) results in a non-conservative amino acid change located in the BRCT domain (IPR001357) of the encoded protein sequence. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change. The variant allele was found at a frequency of 1.2e-05 in 251484 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.5416C>G has been reported in the literature in an individual affected with Hereditary Breast and Ovarian Cancer (Shattuck-Eidens_1997). This report does not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Various functional studies carried out to assess a number of different properties of the variant protein including, transcriptional activity, protein folding, phosphopeptide-binding and thermodynamic stability, all demonstrated the variant to cause no defect and be similar to the wild-type (Carvalho_2007, Coyne_2004, Hayes_2000, Lee_2010, Rowling_2010). The following publications have been ascertained in the context of this evaluation (PMID: 17308087, 15004537, 30765603, 10811118, 20516115, 20378548, 9333265). ClinVar contains an entry for this variant (Variation ID: 55570). Based on the evidence outlined above, the variant was classified as likely benign.
not provided Benign:1
Hereditary breast ovarian cancer syndrome Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at